Senolytic drug reduces cancer resistance to PD-L1 blockade
Resistance to immune checkpoint inhibitors (ICIs), including anti-PD-L1 therapies, remains a major challenge in cancer treatment, with many patients relapsing despite initial responses. Here, we develop a mathematical model to investigate a mechanism of anti-PD-L1 resistance driven by age-associated senescence of CD8 + T cells, in which senescent T cells ( T s ) secrete VEGF, thereby promoting tumor growth through enhanced vascular support. To counteract this effect, we incorporate the senolytic drug navitoclax (ABT-263), which selectively eliminates senescent T cells, and evaluate the efficacy of combined senolytic–anti-PD-L1 therapy in extending tumor remission. Model predictions are validated against independent murine data involving navitoclax and anti-PD-L1 treatment. The model is used to study different strategies of combining the senolytic drug with anti-PD-L1, in order to maximize the remission time of the combined treatment. The optimal starting time of the treatment with the senolytic drug depends on the senescent-to-functional T cells ratio, T s / T . The paper identifies immune senescence as an important determinant of response to cancer immunotherapy.
Authors
- Avner Friedman (ORCID: https://orcid.org/0000-0002-7875-174X)
- Nourridine Siewe (ORCID: https://orcid.org/0000-0002-3005-8508)
Institutions
- Rochester Institute of Technology (US)
- The Ohio State University (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1371/journal.pone.0362939
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00